AAN-Lipo-Dox

AAN-Lipo-Dox is a preclinical liposomal formulation of doxorubicin modified with the legumain protease substrate Ala-Ala-Asn (AAN). Developed by researchers at Nankai University, it serves as a tumor-targeted drug delivery system designed to exploit the overexpression of the cysteine protease legumain in the tumor microenvironment. Legumain cleaves the AAN peptide substrate on the liposome surface, triggering the localized release of the encapsulated cytotoxic payload, doxorubicin. Once released, doxorubicin intercalates into DNA and inhibits topoisomerase II, inducing apoptosis in cancer cells. AAN-Lipo-Dox has been evaluated in preclinical models of solid tumors, such as breast cancer, demonstrating enhanced tumor accumulation and reduced systemic toxicity compared to free doxorubicin.

Other names

AAN-Lipo-DOXAAN-liposomal doxorubicinAAN-modified liposomal doxorubicin